The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oligonucleotide-based Therapies Market Research Report 2025
Synopsis
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
The global Oligonucleotide-based Therapies market was valued at US$ 3678.1 million in 2023 and is anticipated to reach US$ 7749.8 million by 2030, witnessing a CAGR of 11.0% during the forecast period 2024-2030.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide-based Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide-based Therapies.
Report Scope
The Oligonucleotide-based Therapies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oligonucleotide-based Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide-based Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Segment by Application
Neuromuscular Diseases
Hepatic VOD
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide-based Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
The global Oligonucleotide-based Therapies market was valued at US$ 3678.1 million in 2023 and is anticipated to reach US$ 7749.8 million by 2030, witnessing a CAGR of 11.0% during the forecast period 2024-2030.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide-based Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide-based Therapies.
Report Scope
The Oligonucleotide-based Therapies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oligonucleotide-based Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide-based Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Segment by Application
Neuromuscular Diseases
Hepatic VOD
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide-based Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide-based Therapies Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antisense Oligonucleotide
1.2.3 Aptamer
1.2.4 Other
1.3 Market by Application
1.3.1 Global Oligonucleotide-based Therapies Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Neuromuscular Diseases
1.3.3 Hepatic VOD
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide-based Therapies Market Perspective (2019-2030)
2.2 Oligonucleotide-based Therapies Growth Trends by Region
2.2.1 Global Oligonucleotide-based Therapies Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oligonucleotide-based Therapies Historic Market Size by Region (2019-2024)
2.2.3 Oligonucleotide-based Therapies Forecasted Market Size by Region (2025-2030)
2.3 Oligonucleotide-based Therapies Market Dynamics
2.3.1 Oligonucleotide-based Therapies Industry Trends
2.3.2 Oligonucleotide-based Therapies Market Drivers
2.3.3 Oligonucleotide-based Therapies Market Challenges
2.3.4 Oligonucleotide-based Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide-based Therapies Players by Revenue
3.1.1 Global Top Oligonucleotide-based Therapies Players by Revenue (2019-2024)
3.1.2 Global Oligonucleotide-based Therapies Revenue Market Share by Players (2019-2024)
3.2 Global Oligonucleotide-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oligonucleotide-based Therapies Revenue
3.4 Global Oligonucleotide-based Therapies Market Concentration Ratio
3.4.1 Global Oligonucleotide-based Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide-based Therapies Revenue in 2023
3.5 Oligonucleotide-based Therapies Key Players Head office and Area Served
3.6 Key Players Oligonucleotide-based Therapies Product Solution and Service
3.7 Date of Enter into Oligonucleotide-based Therapies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide-based Therapies Breakdown Data by Type
4.1 Global Oligonucleotide-based Therapies Historic Market Size by Type (2019-2024)
4.2 Global Oligonucleotide-based Therapies Forecasted Market Size by Type (2025-2030)
5 Oligonucleotide-based Therapies Breakdown Data by Application
5.1 Global Oligonucleotide-based Therapies Historic Market Size by Application (2019-2024)
5.2 Global Oligonucleotide-based Therapies Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oligonucleotide-based Therapies Market Size (2019-2030)
6.2 North America Oligonucleotide-based Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oligonucleotide-based Therapies Market Size by Country (2019-2024)
6.4 North America Oligonucleotide-based Therapies Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide-based Therapies Market Size (2019-2030)
7.2 Europe Oligonucleotide-based Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oligonucleotide-based Therapies Market Size by Country (2019-2024)
7.4 Europe Oligonucleotide-based Therapies Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide-based Therapies Market Size (2019-2030)
8.2 Asia-Pacific Oligonucleotide-based Therapies Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oligonucleotide-based Therapies Market Size by Region (2019-2024)
8.4 Asia-Pacific Oligonucleotide-based Therapies Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oligonucleotide-based Therapies Market Size (2019-2030)
9.2 Latin America Oligonucleotide-based Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oligonucleotide-based Therapies Market Size by Country (2019-2024)
9.4 Latin America Oligonucleotide-based Therapies Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide-based Therapies Market Size (2019-2030)
10.2 Middle East & Africa Oligonucleotide-based Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oligonucleotide-based Therapies Market Size by Country (2019-2024)
10.4 Middle East & Africa Oligonucleotide-based Therapies Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Oligonucleotide-based Therapies Introduction
11.1.4 Biogen Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.1.5 Biogen Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Detail
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Oligonucleotide-based Therapies Introduction
11.2.4 Sarepta Therapeutics Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Jazz Pharmaceuticals
11.3.1 Jazz Pharmaceuticals Company Detail
11.3.2 Jazz Pharmaceuticals Business Overview
11.3.3 Jazz Pharmaceuticals Oligonucleotide-based Therapies Introduction
11.3.4 Jazz Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.3.5 Jazz Pharmaceuticals Recent Development
11.4 Bausch & Lomb
11.4.1 Bausch & Lomb Company Detail
11.4.2 Bausch & Lomb Business Overview
11.4.3 Bausch & Lomb Oligonucleotide-based Therapies Introduction
11.4.4 Bausch & Lomb Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.4.5 Bausch & Lomb Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Detail
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Dynavax Technologies
11.6.1 Dynavax Technologies Company Detail
11.6.2 Dynavax Technologies Business Overview
11.6.3 Dynavax Technologies Oligonucleotide-based Therapies Introduction
11.6.4 Dynavax Technologies Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.6.5 Dynavax Technologies Recent Development
11.7 Kastle therapeutics
11.7.1 Kastle therapeutics Company Detail
11.7.2 Kastle therapeutics Business Overview
11.7.3 Kastle therapeutics Oligonucleotide-based Therapies Introduction
11.7.4 Kastle therapeutics Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.7.5 Kastle therapeutics Recent Development
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Detail
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Oligonucleotide-based Therapies Introduction
11.8.4 Akcea Therapeutics Revenue in Oligonucleotide-based Therapies Business (2019-2024)
11.8.5 Akcea Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Oligonucleotide-based Therapies Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Antisense Oligonucleotide
Table 3. Key Players of Aptamer
Table 4. Key Players of Other
Table 5. Global Oligonucleotide-based Therapies Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Oligonucleotide-based Therapies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Oligonucleotide-based Therapies Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Oligonucleotide-based Therapies Market Share by Region (2019-2024)
Table 9. Global Oligonucleotide-based Therapies Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Oligonucleotide-based Therapies Market Share by Region (2025-2030)
Table 11. Oligonucleotide-based Therapies Market Trends
Table 12. Oligonucleotide-based Therapies Market Drivers
Table 13. Oligonucleotide-based Therapies Market Challenges
Table 14. Oligonucleotide-based Therapies Market Restraints
Table 15. Global Oligonucleotide-based Therapies Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Oligonucleotide-based Therapies Market Share by Players (2019-2024)
Table 17. Global Top Oligonucleotide-based Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide-based Therapies as of 2023)
Table 18. Ranking of Global Top Oligonucleotide-based Therapies Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Oligonucleotide-based Therapies Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Oligonucleotide-based Therapies Product Solution and Service
Table 22. Date of Enter into Oligonucleotide-based Therapies Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oligonucleotide-based Therapies Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Oligonucleotide-based Therapies Revenue Market Share by Type (2019-2024)
Table 26. Global Oligonucleotide-based Therapies Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Oligonucleotide-based Therapies Revenue Market Share by Type (2025-2030)
Table 28. Global Oligonucleotide-based Therapies Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Oligonucleotide-based Therapies Revenue Market Share by Application (2019-2024)
Table 30. Global Oligonucleotide-based Therapies Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Oligonucleotide-based Therapies Revenue Market Share by Application (2025-2030)
Table 32. North America Oligonucleotide-based Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Oligonucleotide-based Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Oligonucleotide-based Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Oligonucleotide-based Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Oligonucleotide-based Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Oligonucleotide-based Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Oligonucleotide-based Therapies Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Oligonucleotide-based Therapies Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Oligonucleotide-based Therapies Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Oligonucleotide-based Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Oligonucleotide-based Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Oligonucleotide-based Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Oligonucleotide-based Therapies Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Oligonucleotide-based Therapies Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Oligonucleotide-based Therapies Market Size by Country (2025-2030) & (US$ Million)
Table 47. Biogen Company Detail
Table 48. Biogen Business Overview
Table 49. Biogen Oligonucleotide-based Therapies Product
Table 50. Biogen Revenue in Oligonucleotide-based Therapies Business (2019-2024) & (US$ Million)
Table 51. Biogen Recent Development
Table 52. Sarepta Therapeutics Company Detail
Table 53. Sarepta Therapeutics Business Overview
Table 54. Sarepta Therapeutics Oligonucleotide-based Therapies Product
Table 55. Sarepta Therapeutics Revenue in Oligonucleotide-based Therapies Business (2019-2024) & (US$ Million)
Table 56. Sarepta Therapeutics Recent Development
Table 57. Jazz Pharmaceuticals Company Detail
Table 58. Jazz Pharmaceuticals Business Overview
Table 59. Jazz Pharmaceuticals Oligonucleotide-based Therapies Product
Table 60. Jazz Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2019-2024) & (US$ Million)
Table 61. Jazz Pharmaceuticals Recent Development
Table 62. Bausch & Lomb Company Detail
Table 63. Bausch & Lomb Business Overview
Table 64. Bausch & Lomb Oligonucleotide-based Therapies Product
Table 65. Bausch & Lomb Revenue in Oligonucleotide-based Therapies Business (2019-2024) & (US$ Million)
Table 66. Bausch & Lomb Recent Development
Table 67. Alnylam Pharmaceuticals Company Detail
Table 68. Alnylam Pharmaceuticals Business Overview
Table 69. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Product
Table 70. Alnylam Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2019-2024) & (US$ Million)
Table 71. Alnylam Pharmaceuticals Recent Development
Table 72. Dynavax Technologies Company Detail
Table 73. Dynavax Technologies Business Overview
Table 74. Dynavax Technologies Oligonucleotide-based Therapies Product
Table 75. Dynavax Technologies Revenue in Oligonucleotide-based Therapies Business (2019-2024) & (US$ Million)
Table 76. Dynavax Technologies Recent Development
Table 77. Kastle therapeutics Company Detail
Table 78. Kastle therapeutics Business Overview
Table 79. Kastle therapeutics Oligonucleotide-based Therapies Product
Table 80. Kastle therapeutics Revenue in Oligonucleotide-based Therapies Business (2019-2024) & (US$ Million)
Table 81. Kastle therapeutics Recent Development
Table 82. Akcea Therapeutics Company Detail
Table 83. Akcea Therapeutics Business Overview
Table 84. Akcea Therapeutics Oligonucleotide-based Therapies Product
Table 85. Akcea Therapeutics Revenue in Oligonucleotide-based Therapies Business (2019-2024) & (US$ Million)
Table 86. Akcea Therapeutics Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oligonucleotide-based Therapies Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Oligonucleotide-based Therapies Market Share by Type: 2023 VS 2030
Figure 3. Antisense Oligonucleotide Features
Figure 4. Aptamer Features
Figure 5. Other Features
Figure 6. Global Oligonucleotide-based Therapies Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Oligonucleotide-based Therapies Market Share by Application: 2023 VS 2030
Figure 8. Neuromuscular Diseases Case Studies
Figure 9. Hepatic VOD Case Studies
Figure 10. Other Case Studies
Figure 11. Oligonucleotide-based Therapies Report Years Considered
Figure 12. Global Oligonucleotide-based Therapies Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Oligonucleotide-based Therapies Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Oligonucleotide-based Therapies Market Share by Region: 2023 VS 2030
Figure 15. Global Oligonucleotide-based Therapies Market Share by Players in 2023
Figure 16. Global Top Oligonucleotide-based Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide-based Therapies as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Oligonucleotide-based Therapies Revenue in 2023
Figure 18. North America Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Oligonucleotide-based Therapies Market Share by Country (2019-2030)
Figure 20. United States Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Oligonucleotide-based Therapies Market Share by Country (2019-2030)
Figure 24. Germany Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Oligonucleotide-based Therapies Market Share by Region (2019-2030)
Figure 32. China Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Oligonucleotide-based Therapies Market Share by Country (2019-2030)
Figure 40. Mexico Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Oligonucleotide-based Therapies Market Share by Country (2019-2030)
Figure 44. Turkey Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Oligonucleotide-based Therapies Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Biogen Revenue Growth Rate in Oligonucleotide-based Therapies Business (2019-2024)
Figure 47. Sarepta Therapeutics Revenue Growth Rate in Oligonucleotide-based Therapies Business (2019-2024)
Figure 48. Jazz Pharmaceuticals Revenue Growth Rate in Oligonucleotide-based Therapies Business (2019-2024)
Figure 49. Bausch & Lomb Revenue Growth Rate in Oligonucleotide-based Therapies Business (2019-2024)
Figure 50. Alnylam Pharmaceuticals Revenue Growth Rate in Oligonucleotide-based Therapies Business (2019-2024)
Figure 51. Dynavax Technologies Revenue Growth Rate in Oligonucleotide-based Therapies Business (2019-2024)
Figure 52. Kastle therapeutics Revenue Growth Rate in Oligonucleotide-based Therapies Business (2019-2024)
Figure 53. Akcea Therapeutics Revenue Growth Rate in Oligonucleotide-based Therapies Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
